Abstract 236P
Background
Nasopharyngeal carcinoma is a disease unique to Southeast Asia. Radiotherapy and chemotherapy serve as the standard treatment mode for locally advanced nasopharyngeal carcinoma (LANPC), but the efficacy is not ideal due to local recurrence and distant metastasis. Meanwhile, studies have shown concurrent chemoradiotherapy will aggravate treatment-related side effects. Chrono-chemotherapy is to select the appropriate timing of administration according to the biological rhythm of the human body, in order to improve the efficacy and reduce side effects. At present, most studies on the treatment of LANPC by hourly chemotherapy combined with radiotherapy are single-center and small-sample studies, lacking evidence-based medical evidence. Therefore, we adopted the method of meta-analysis to evaluate the efficacy and safety of chemotherapy combined with radiotherapy for LANPC in existing studies, in order to provide reference for clinical treatment.
Methods
Seven databases were searched, including the Cochrane Library (Issue 5, 2021), Pubmed, Embase, CBM, CNKI, VIP and Wanfang Database. The meta-analysis was performed by the Revman 5.3 software.
Results
Thirteen studies containing 901 patients were finally included. Compared with the conventional chemotherapy group, results showed that the effective rate, adverse reactions and immune function of the chrono-chemotherapy group was significantly higher than that of the conventional chemotherapy group. Chrono-chemotherapy combined with radiotherapy can increase the effective rate (P<0.001), and the CD3, CD, CD4/CD8 were higher than the conventional chemotherapy group (P<0.001), at the same time, chrono-chemotherapy group cloud reduce the III-IV°leucopenia, thrombocytopenia, gastrointestinal reaction, oral mucosa reaction, radiothermitis (P<0.001).
Conclusions
Current evidence shows that compared with the conventional chemotherapy group, the chrono-chemotherapy with radiotherapy could improve the effective rate and immune function, and reduce adverse reactions at the same time.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
214P - Versican G3 domain promotes myeloma cell proliferation, migration and invasion via activation of FAK/STAT3 signaling
Presenter: Nidhi Gupta
Session: Poster viewing 03
215P - Prospective observational study to evaluate impact of metabolic tumor volume on baseline 18F FDG PET/CT and molecular markers on tumor response rate in patients with diffuse large B-cell lymphoma
Presenter: Ankur Mudgal
Session: Poster viewing 03
216P - Lenalidomide maintenance after whole brain radiotherapy in relapsed/refractory primary CNS lymphoma
Presenter: Bhausaheb Bagal
Session: Poster viewing 03
217P - Role of copper levels in patients with myelodysplastic syndromes
Presenter: Revanth Boddu
Session: Poster viewing 03
218P - Prognostic role of apoptotic index in acute lymphoblastic leukemia
Presenter: Ramya Ramesh
Session: Poster viewing 03
219TiP - Randomised controlled study to compare efficacy & safety of KRd versus VRd regimens in newly diagnosed multiple myeloma using weekly schedule of generic carfilzomib
Presenter: Jasmine Porwal
Session: Poster viewing 03
233P - Cancer awareness, tobacco use and cessation among Malayali tribes, Yelagiri Hills, Tamil Nadu, India: A 8-year follow up study
Presenter: Delfin Lovelina Francis
Session: Poster viewing 03
234P - Epithelial-mesenchymal transition and cancer stem cells: Missing link in oral squamous cell carcinoma
Presenter: Selvaraj Jayaraman
Session: Poster viewing 03
235P - Evaluation of a prognostic model for head and neck cutaneous squamous cell carcinoma using a cumulative number of risk factors
Presenter: Reiichi Doi
Session: Poster viewing 03